Disc Medicine, Inc.
Close on Oct 19, 2026
- Market cap
- $3.05B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | $-1.65 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-1.77 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.89 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
Press releases
Announcements Disc Medicine filed with the SEC
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
APOLLO Topline Results October 19,
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14 th Society of Hematologic Oncology (SOHO) Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bitopertin Regulatory Update February 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Certain identified information has been excluded from this exhibit. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J.P. Morgan 44th Annual Healthcare Conference Corporate Overview January 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
2025 ASH Management Call December 7, 2025 Confidential Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclaimer and FLS This presentation contains “forward-looking
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2024 ASH Management Call Clinical Data Updates: Bitopertin, DISC-0974, and DISC-3405 December 8, 2024 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bitopertin End of Phase 2 Meeting Feedback November 4, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Announces Underwritten Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclaimer and FLS This presentation includes “forward-looking
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as
Regulation FD disclosure · EX-99.1 to Form 8-K
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K